 Connection
David Raben to Signal Transduction
This is a "connection" page, showing publications David Raben has written about Signal Transduction.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.691 |
|
|
|
-
Raben D, Bianco C, Helfrich B, Weng E, Ciardiello F, Harari P. Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment. Expert Rev Anticancer Ther. 2002 Aug; 2(4):461-71.
Score: 0.078
-
Raben DM, Baldassare JJ. Phospholipid metabolism and nuclear envelope signaling. Adv Enzyme Regul. 2000; 40:97-123.
Score: 0.065
-
Raben DM, Baldassare JJ. Nuclear envelope signaling-role of phospholipid metabolism. Eur J Histochem. 2000; 44(1):67-80.
Score: 0.065
-
Bhatia S, Oweida A, Lennon S, Darragh LB, Milner D, Phan AV, Mueller AC, Van Court B, Raben D, Serkova NJ, Wang XJ, Jimeno A, Clambey ET, Pasquale EB, Karam SD. Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers. Cancer Res. 2019 05 15; 79(10):2722-2735.
Score: 0.062
-
Cheng J, Baldassare JJ, Raben DM. Dual coupling of the alpha-thrombin receptor to signal-transduction pathways involving phosphatidylinositol and phosphatidylcholine metabolism. Biochem J. 1999 Jan 01; 337 ( Pt 1):97-104.
Score: 0.061
-
Yom SS, Diehn M, Raben D. Molecular determinants of radiation response in non-small cell lung cancer. Semin Radiat Oncol. 2015 Apr; 25(2):67-77.
Score: 0.046
-
Raben DM, Jarpe MB, Leach KL. Nuclear lipid metabolism in NEST: Nuclear Envelope Signal Transduction. J Membr Biol. 1994 Oct; 142(1):1-7.
Score: 0.045
-
Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol. 2008 Feb; 61(2):179-88.
Score: 0.027
-
Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I, Raben D. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Jan 01; 64(1):33-7.
Score: 0.025
-
Song J, Chen C, Raben D. Emerging role of EGFR-targeted therapies and radiation in head and neck cancer. Oncology (Williston Park). 2004 Dec; 18(14):1757-67; discussion 1767, 1771-2, 1777.
Score: 0.023
-
Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther. 2004 Aug; 3(8):977-83.
Score: 0.022
-
Raben D, Bianco C, Milas L, Ang KK. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? Semin Radiat Oncol. 2004 Apr; 14(2):139-52.
Score: 0.022
-
Tu-Sekine B, Raben DM. Nuclear production and metabolism of diacylglycerol. Eur J Histochem. 2004; 48(1):77-82.
Score: 0.021
-
Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):37-46.
Score: 0.019
-
Lennon S, Oweida A, Milner D, Phan AV, Bhatia S, Van Court B, Darragh L, Mueller AC, Raben D, Mart?nez-Torrecuadrada JL, Pitts TM, Somerset H, Jordan KR, Hansen KC, Williams J, Messersmith WA, Schulick RD, Owens P, Goodman KA, Karam SD. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. Clin Cancer Res. 2019 06 01; 25(11):3352-3365.
Score: 0.015
-
Luo J, Bian L, Blevins MA, Wang D, Liang C, Du D, Wu F, Holwerda B, Zhao R, Raben D, Zhou H, Young CD, Wang XJ. Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model. Clin Cancer Res. 2019 01 15; 25(2):808-818.
Score: 0.015
-
Bhatia S, Griego A, Lennon S, Oweida A, Sharma J, Rohmer C, Uyanga N, Bukkapatnam S, Van Court B, Raben D, Young C, Heasley L, Karam SD. Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor. Mol Cancer Ther. 2018 09; 17(9):2049-2059.
Score: 0.015
-
Bhatia S, Sharma J, Bukkapatnam S, Oweida A, Lennon S, Phan A, Milner D, Uyanga N, Jimeno A, Raben D, Somerset H, Heasley L, Karam SD. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers. Clin Cancer Res. 2018 09 15; 24(18):4539-4550.
Score: 0.015
-
Gan GN, Eagles J, Keysar SB, Wang G, Glogowska MJ, Altunbas C, Anderson RT, Le PN, Morton JJ, Frederick B, Raben D, Wang XJ, Jimeno A. Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers. Cancer Res. 2014 Dec 01; 74(23):7024-36.
Score: 0.011
-
Han G, Bian L, Li F, Cotrim A, Wang D, Lu J, Deng Y, Bird G, Sowers A, Mitchell JB, Gutkind JS, Zhao R, Raben D, ten Dijke P, Refaeli Y, Zhang Q, Wang XJ. Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med. 2013 Apr; 19(4):421-8.
Score: 0.010
-
Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2011 Aug 01; 17(15):5016-25.
Score: 0.009
-
Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008 May 17; 371(9625):1695-709.
Score: 0.007
-
Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Ricciardi S, Del Tacca M, Raben D, Cionini L, Danesi R. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res. 2006 Dec 01; 12(23):7099-107.
Score: 0.007
-
Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Bar?n A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 01; 12(23):7117-25.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|